The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial

English version České info

Background:
It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3–59 months.

Methods and Findings:
We used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL.

Conclusions:
Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale.

Trial Registration: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial. PLoS Med 8(5): e32767. doi:10.1371/journal.pmed.1000437
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000437

Souhrn

Zdroje

1. World Health Organisation

2006

Guidelines for the treatment of malaria, second edition. Available: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html. Accessed 1 May 2010

2. World Health Organisation

2009

World Malaria Report. Available: http://www.who.int/malaria/world_malaria_report_2009/en/index.html. Accessed 1 May 2010

3. Institute of Medicine of the National Academies

2004

Saving Lives, Buying Time.

Economics of Malaria Drugs in an Age of Resistance

Washington DC

National Academies Press

4. McCombieSC

1996

Treatment seeking for malaria: a review of recent research.

Soc Sci Med

933

945

5. WilliamsHA

JonesCO

2004

A critical review of behavioral issues related to malaria control in sub-Saharan Africa: what contributions have social scientists made?

Soc Sci Med

501

523

6. LaxminarayanR

ParryIWH

SmithDL

KleinE

2010

Should new antimalarial drugs be subsidised.

J Health Econ

445

456

7. Roll Back Malaria

2007

Affordable Medicines Facility – malaria.

Available: http://www.rollbackmalaria.org/partnership/tf/globalsubsidy/AMFmTechProposal.pdf. Accessed 5 May 2010

8. TalisunaA

GrewalP

RwakimariJB

MukasaS

JagoeG

2009

Cost is killing patients: Subsidising effective antimalarials.

Lancet

374

1224

1226

9. SabotOJ

MwitaA

CohenJM

IpugeY

GordonM

2009

Piloting the global subsidy: The impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania.

PLoS ONE

e6857

doi:10.1371/journal.pone.0006857

10. GoodmanC

BriegerW

UnwinA

MillsA

MeekS

2007

Medicine Sellers and Treatment in sub-Saharan Africa: What do they do and how can their practice be improved?

Am J Trop Med Hyg

(Suppl6)

203

218

11. SmithLA

JonesC

MeekS

WebsterJ

2009

Provider practice and user behavior interventions to improve prompt and effective treatment of malaria: Do we know what works?

Am J Trop Med Hyg

326

335

12. SabotO

YeungS

PagnoniF

GordonM

PettyN

2009

Distribution of artemisinin-based combination therapies through private-sector channels.

RFF Discussion Paper

13. D'AlessandroU

TalisunaM

BoelaertM

2005

Should artemisinin-based combination treatment be used in the home-based manaalaria.

Trop Med Int Health

14. Oxfam

2009

Blind optimism: Challenging the myths about private healthcare in poor countries.

Oxfam Briefing Paper

Available: http://www.oxfam.org/sites/www.oxfam.org/files/bp125-blind-optimism-0902.pdf. Accessed: 3 May 2010

15. Exchange rate.com. Available: http://www.exchangerate.com/past_rates_entry.html. Accessed 13 April 2010

16. Central Bureau of Statistics

2003

Geographic dimensions of well-being in Kenya, Where are the poor?

From districts to locations, volume I. Central Bureau of Statistics, Ministry of Planning and National Development, Government of Kenya

17. NoorAM

GethingPM

AleganaVM

PatilA

HaySI

2009

The risks of malaria infection in Kenya.

BMC Infectious Diseases

180

18. Central Bureau of Statistics, Kenya

1999

19. NoorA

KEMRI Wellcome Trust Research Programme.

Unpublished data

20. KangwanaBB

NjoguJ

WasunnaB

KedengeSV

MemusiDN

2009

Malaria drug shortages in Kenya: A major failure to provide access to effective treatment.

Am J Trop Med Hyg

737

738

21. ChumaJ

MusimbiJ

OkunguV

GoodmanG

MolyneuxC

2009

Reducing user fees for primary health care in Kenya: Policy on paper or policy in practice?

Int J Equity Health

22. ZurovacD

NjoguJ

AkhwaleW

HamerD

SnowR

2008

Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: An early experience from Kenya.

Trop Med Int Health

107

23. WasunnaB

ZurovacD

GoodmanCA

SnowRW

2008

Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine.

Malar J

24. RobinsonC

2002

Real World Research: A Resource for Social Scientists and Practitioner-researchers, Second edition.

Oxford

Blackwell

25. MarshVM

MutemiWM

WillettsA

BayahK

WereS

2004

Improving malaria home treatment by training drug retailers in rural Kenya.

Trop Med Int Health

451

460

26. KangwanaB

KedengeS

NoorA

AleganaV

NyandigisiA

2010

The impact of retail sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya - A cluster randomized controlled trial.

Provider survey. Unpublished report, Population Services International, Kenya

27. GitongaCW

AminA

AjangaA

KangwanaBB

NoorAM

2008

The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya.

Trop Med Int Health

487

494

28. Gikonyo C. KEMRI Wellcome Trust Research Programme.

Unpublished data

29. HayesRJ

MoultonLH

2009

Cluster Randomised Trials.

Boca Raton

CRC Press

30. Central Bureau of Statistics (CBS) [Kenya], Ministry of Health (MOH) [Kenya], and ORC Marco

2004

Kenya Demographic Health Survey 2003 Calverton, Maryland: CBS, MOH, and ORC Marco

31. FilmerD

PritchettLH

2001

Estimating wealth effects without expenditure data—Or tears: An application to educational enrolments in states of India.

Demography

115

132

32. KangwanaB

KEMRI Wellcome Trust Research Programme.

Unpublished data

33. ZurovacD

NdhlovuM

SipilanyambeN

ChandaP

HamerDH

2007

Paediatric malaria case-management with artemether-lumefantrine in Zambia: A repeat cross-sectional study.

Malar J

34. Division of Malaria Control, Kenya

2010

Monitoring Outpatient Malaria Case Management under the 2010 Diagnostic and Treatment Policy in Kenya

35. YeungS

WhiteNJ

2005

How do patients use antimalarial drugs? A review of the evidence.

Trop Med Intl Health

121

138

36. DepoortereE

GuthmannJP

SipilanyambeN

NkanduE

FermonF

2004

Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia.

Trop Med Int Health

37. FoggC

BajunirweF

PiolaP

BiraroS

ChecchiF

2004

Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda.

Am J Trop Med Hyg

525

530

38. KachurSP

KhatibRA

KaizerE

FoxSS

AbdullaSM

2004

Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania.

Am J Trop Med Hyg

715

722

39. BeerN

AliAS

RotllantG

AbassAK

OmariRS

2009

Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania.

Trop Med Int Health

766

774

40. NjoguJ

AkhwaleW

HamerDH

ZurovacD

2008

Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya.

East Afr Med J

213

221

41. KedengeS

KangwanaB

NoorA

AleganaV

NyandigisiA

2010

The impact of retail sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya - A cluster randomized controlled trial.

Focus Group Discussions. Unpublished report, Population Services International, Kenya

42. AjayiIO

BrowneEN

GarshongB

BateganyaF

YusufB

2009

Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites.

Malar J

43. WafulaF

GoodmanC

2010

Are interventions for improving the quality of services provided by specialized drug shops effective in sub-Saharan Africa? A systematic review of the literature.

Int J Qual Health Care

316

323

44. HopkinsH

TalisunaA

WhittyJ

StaedkeS

2007

Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence.

Malar J

134

45. SmithF

2009

The quality of private pharmacy services in low and middle-income countries: a systematic review.

Pharm World Sci

351

361

46. HabichtJP

VictoraCG

VaughanJP

1999

Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact.

Int J Epidemiol

47. VandenbrouckeJP

2008

Observational research, randomised trials, and two views of medical science.

PLoS Med

e67

doi:10.1371/journal.pmed.0050067

48. VictoraCG

HabichtJP

BryceJ

2004

Evidence-based public health: Moving beyond randomized trials.

Am J Public Health

400

405

49. AtkinsD

2007

Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.

Med Care

16S

22S

50. The Roll Back Malaria Strategy for Improving Access to Treatment Through Home Management of Malaria; WHO/HTM/MAL/2005/110. Available: http://www.searo.who.int/LinkFiles/Reports_RBM_Strategy.pdf

51. PagnoniF

2009

Malaria treatment: no place like home.

Trends Parasitol

115

119

52. Division of Malaria Control, Kenya

2009

Malaria Indicator Survey

53. RoweA

LamaM

OnikpoF